AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2278060 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sulfadoxine-pyrimethamine
Number of subjects: 186
Study 2278060 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular sulfadoxine-pyrimethamine
Number of subjects: 186
Study 2278060 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 186
Study 396652 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (100 mg/day, 25 mg in the morning and midday and 50 mg at bed time)
Number of subjects: 96
Study 396652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 29203731 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy plus rescue therapy for ICAS
Number of subjects: 140
Study 29203731 — intervention group
Group type: COMPARATOR
Intervention: Embolic group
Number of subjects: 140
Study 27537997 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone gel, 7.5%
Number of subjects: 2238
Study 27537997 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 2238
Study 24377485 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve block (group A)
Number of subjects: 60
Study 24377485 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling catheter-based multiple infiltrations of bupivacaine (group B)
Number of subjects: 60
Study 24377485 — intervention group
Group type: COMPARATOR
Intervention: Single dose of 0.5% bupivacaine infiltration (group C)
Number of subjects: 60
Study 22274319 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachytherapy with a total dose of 15Gy to point A followed by radical surgery (arm BT)
Number of subjects: 123
Study 22274319 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous chemotherapy with cisplatin 50 mg/m plus 5‐fluorouracil 750 mg/m at a 2‐week interval for 2 courses followed by radical surgery (arm IVCT)
Number of subjects: 123
Study 22274319 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial chemotherapy with the same regimen as the IVCT arm followed by radical surgery (arm IACT)
Number of subjects: 123
Study 22274319 — intervention group
Group type: COMPARATOR
Intervention: Radical surgery alone (arm RS)
Number of subjects: 123
Study 20858029 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving intervention
Number of subjects: 50
Study 20858029 — intervention group
Group type: COMPARATOR
Intervention: Camp as usual
Number of subjects: 50
Study 20858029 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined groups (problem-solving intervention and camp as usual)
Number of subjects: 50
Study 17690950 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine treatment (2 g taurine 3 times a day for three months)
Number of subjects: 24
Study 17690950 — intervention group
Group type: COMPARATOR
Intervention: Placebo (without taurine for 4 months)
Number of subjects: 24
Study 17690950 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine treatment
Number of subjects: 24
Study 17690950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 16858546 — intervention group
Group type: EXPERIMENTAL
Intervention: PHRSD
Number of subjects: 32
Study 16858546 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y PPPD
Number of subjects: 32
Study 12544522 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group (n = 10 townships)
Number of subjects: 4299
Study 12544522 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 11 townships)
Number of subjects: 4299
Study 10472562 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine, Actinomycin D, Cyclophosphamide or Ifosfamide, Adriamycin (Doxorubicin), with or without Etoposide
Number of subjects: 631
Study 8671497 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic-free medium
Number of subjects: 196
Study 8671497 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium modified with half the standard antibiotic concentration
Number of subjects: 196
Study 8671497 — intervention group
Group type: COMPARATOR
Intervention: Conventional medium (control group)
Number of subjects: 196
Study 1917610 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam irradiation
Number of subjects: 104
Study 6162389 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of compound 48/80
Number of subjects: 25
Study 6162389 — intervention group
Group type: COMPARATOR
Intervention: Histamine H1 receptor antagonist, antazoline phosphate
Number of subjects: 25
Study 6140441 — intervention group
Group type: EXPERIMENTAL
Intervention: Component vaccine containing purified haemagglutinins (HAs) of Bordetella pertussis
Number of subjects: 5000
Study 6140441 — intervention group
Group type: COMPARATOR
Intervention: Conventional whole-cell vaccine
Number of subjects: 5000
Study 30903525 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Nd:YAG laser (1064 nm) applied at 3000 J with 20 J/cm2 for 15 min
Number of subjects: 30
Study 30903525 — intervention group
Group type: COMPARATOR
Intervention: Control side (no intervention)
Number of subjects: 30
Study 29626849 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine at the ED95 dose (0.128 mg/kg)
Number of subjects: 60
Study 29626849 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil at an equivalent dose
Number of subjects: 60
Study 29939698 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprocedural flurbiprofen axetil
Number of subjects: 52
Study 29939698 — intervention group
Group type: COMPARATOR
Intervention: Oxybuprocaine jelly alone
Number of subjects: 52
Study 23887713 — intervention group
Group type: EXPERIMENTAL
Intervention: Phospho-histone H3 (pHH3) expression
Number of subjects: 339
Study 23887713 — intervention group
Group type: COMPARATOR
Intervention: Ki-67 expression
Number of subjects: 339
Study 23887713 — intervention group
Group type: EXPERIMENTAL
Intervention: pHH3 expression
Number of subjects: 339
Study 22468945 — intervention group
Group type: EXPERIMENTAL
Intervention: Concord grape juice for 16 weeks
Number of subjects: 0
Study 22468945 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 16 weeks
Number of subjects: 0
Study 20886801 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicated thread moxibustion of traditional Zhuang nationality medicine
Number of subjects: 150
Study 20886801 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple plum-blossom needle
Number of subjects: 150
Study 20886801 — intervention group
Group type: EXPERIMENTAL
Intervention: Plum-blossom needle combined with medicated thread moxibustion
Number of subjects: 150
Study 17875030 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported Group Residence (SGR)
Number of subjects: 0
Study 17875030 — intervention group
Group type: COMPARATOR
Intervention: Inpatient group (Control)
Number of subjects: 0
Study 16163530 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 42
Study 16163530 — intervention group
Group type: COMPARATOR
Intervention: Balanced (placebo) amino acid mixture
Number of subjects: 42
Study 11882622 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg/d) for up to 5 weeks
Number of subjects: 7
Study 11882622 — intervention group
Group type: COMPARATOR
Intervention: Control (no ACEi treatment), n=7
Number of subjects: 7
Study 10431866 — intervention group
Group type: EXPERIMENTAL
Intervention: Washed postoperative drainage fluid (Group A)
Number of subjects: 112
Study 10431866 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 112
Study 7581139 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron infusion for 3 days during CY administration
Number of subjects: 60
Study 7581139 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron infusion for 7 days during Bu/CY administration
Number of subjects: 60
Study 7581139 — intervention group
Group type: COMPARATOR
Intervention: MCP plus droperidol
Number of subjects: 60
Study 2213777 — intervention group
Group type: EXPERIMENTAL
Intervention: Numerical Rating Scale (NRS)
Number of subjects: 91
Study 2213777 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS)
Number of subjects: 91
Study 2213777 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal Rating Scale (VRS)
Number of subjects: 91
Study 121048 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg oestriol + 2 mg oestradiol
Number of subjects: 4
Study 121048 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg oestriol succinate + 1 mg oestradiol
Number of subjects: 4
Study 121048 — intervention group
Group type: EXPERIMENTAL
Intervention: oestriol succinate
Number of subjects: 4
Study 121048 — intervention group
Group type: COMPARATOR
Intervention: 2 mg oestradiol
Number of subjects: 4
Study 121048 — intervention group
Group type: COMPARATOR
Intervention: 1 mg oestradiol
Number of subjects: 4
Study 31864960 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant-directed (ID) speech
Number of subjects: 37
Study 31864960 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult-directed (AD) speech
Number of subjects: 37
Study 31864960 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle ringtones and ID speech
Number of subjects: 37
Study 31864960 — intervention group
Group type: EXPERIMENTAL
Intervention: Categorical mismatch (human speech to furniture target images)
Number of subjects: 37
Study 31864960 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle ringtones
Number of subjects: 37
Study 30504059 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (1 mg)
Number of subjects: 23
Study 30504059 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 23
Study 30504059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 28966211 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose PCV13 followed by PPV23 after 16 weeks (bDMARD)
Number of subjects: 100
Study 28966211 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose PCV13 followed by PPV23 after 24 weeks (bDMARD)
Number of subjects: 100
Study 28966211 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose PCV13 followed by PPV23 after 16 weeks (bDMARD)
Number of subjects: 100
Study 28966211 — intervention group
Group type: COMPARATOR
Intervention: Single dose PCV13 followed by PPV23 after 16 weeks (csDMARD)
Number of subjects: 100
Study 28966211 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab-treated participants (bDMARD)
Number of subjects: 100
Study 27030901 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication partner training (JOINT)
Number of subjects: 44
Study 27030901 — intervention group
Group type: EXPERIMENTAL
Intervention: TBI SOLO
Number of subjects: 44
Study 27030901 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (CTRL)
Number of subjects: 44
Study 24393750 — intervention group
Group type: EXPERIMENTAL
Intervention: Raisins
Number of subjects: 46
Study 24393750 — intervention group
Group type: COMPARATOR
Intervention: Snacks
Number of subjects: 46
Study 22119746 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine orally disintegrating tablet (ODT) - mean dosage 15.2 mg
Number of subjects: 118
Study 22119746 — intervention group
Group type: COMPARATOR
Intervention: Oral standard tablet (OST) - mean dosage 15.7 mg
Number of subjects: 118
Study 22119746 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine ODT
Number of subjects: 118
Study 22119746 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine OST
Number of subjects: 118
Study 19351725 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 116
Study 19351725 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 116
Study 17584312 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (2 mg/kg/day in three divided doses for 3 days)
Number of subjects: 59
Study 17584312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 15020038 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg ibuprofen for 14 days
Number of subjects: 1000
Study 15020038 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo for 14 days
Number of subjects: 1000
Study 10953784 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitative coping skills module employing problem solving and cognitive behavioral therapy (experimental group)
Number of subjects: 99
Study 10953784 — intervention group
Group type: COMPARATOR
Intervention: Control group of comparable schizophrenics
Number of subjects: 99
Study 9117953 — intervention group
Group type: EXPERIMENTAL
Intervention: Source control system with supplemental oxygen and exhalent scavenged
Number of subjects: 22
Study 9117953 — intervention group
Group type: COMPARATOR
Intervention: Routine care with supplemental oxygen by nasal prong
Number of subjects: 22
Study 8458362 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril once daily (o.d.)
Number of subjects: 32
Study 8458362 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril twice daily (b.i.d.)
Number of subjects: 32
Study 8458362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 3535399 — intervention group
Group type: COMPARATOR
Intervention: Carbenicillin 10 g every 8 h plus Gentamicin 80 mg every 8 h
Number of subjects: 56
Study 3535399 — intervention group
Group type: EXPERIMENTAL
Intervention: Latamoxef 2 g every 8 h
Number of subjects: 56
Study 3535399 — intervention group
Group type: COMPARATOR
Intervention: Carbenicillin 10 g every 8 h plus Mecillinam 800 mg every 8 h
Number of subjects: 56
Study 31298078 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar Spine Instability questionnaire
Number of subjects: 172
Study 30539540 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential amino acid supplementation (Aminotrofic®) at 8g/day (two sachets of 4g/day)
Number of subjects: 32
Study 30539540 — intervention group
Group type: COMPARATOR
Intervention: Physical exercise rehabilitative programme and dietetic counseling
Number of subjects: 32
Study 27879555 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP5-IPV
Number of subjects: 3270
Study 27879555 — intervention group
Group type: COMPARATOR
Intervention: DTaP5+IPV
Number of subjects: 3270
Study 27879555 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 3270
Study 24652866 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoarthritis (OA) label
Number of subjects: 0
Study 24652866 — intervention group
Group type: COMPARATOR
Intervention: No OA label
Number of subjects: 0
Study 24217362 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitory rTMS over the contralesional IFG followed by SLT
Number of subjects: 31
Study 24217362 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation followed by SLT
Number of subjects: 31
Study 24217362 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitory rTMS over the contralesional IFG for left-handed patients
Number of subjects: 31
Study 21212710 — intervention group
Group type: EXPERIMENTAL
Intervention: TCI of REM + PRO
Number of subjects: 60
Study 21212710 — intervention group
Group type: COMPARATOR
Intervention: FEN bolus infusion + DES inhalation
Number of subjects: 60
Study 18643722 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on the LAP Mentor VR simulator (6 sessions of 30 minutes each)
Number of subjects: 32
Study 18643722 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 32
Study 16826829 — intervention group
Group type: EXPERIMENTAL
Intervention: Asking for the referent of a novel label
Number of subjects: 40
Study 16826829 — intervention group
Group type: COMPARATOR
Intervention: Asking a non-specific question
Number of subjects: 40
Study 15071277 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual chamber pacing mode
Number of subjects: 506
Study 15071277 — intervention group
Group type: COMPARATOR
Intervention: Ventricular backup pacing
Number of subjects: 506
Study 11789241 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated traditional Chinese and Western medicine (TCM‐WM) therapy using Jiangtang Janshenling (JTJSL) capsule, alongside western medicine for blood glucose control, for three months.
Number of subjects: 100
Study 11789241 — intervention group
Group type: COMPARATOR
Intervention: Western medicine alone for three months.
Number of subjects: 100
Study 11789241 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated traditional Chinese and Western medicine (TCM‐WM) therapy.
Number of subjects: 100
Study 11789241 — intervention group
Group type: COMPARATOR
Intervention: Western medicine alone.
Number of subjects: 100
Study 9110906 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine-prilocaine cream
Number of subjects: 68
Study 9110906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 8467540 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone
Number of subjects: 59
Study 8467540 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 59
Study 8467540 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 59
Study 3004799 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of aqueous solutions with varying chloride ion concentrations
Number of subjects: 0
Study 3004799 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of ultrasonically nebulized fluid
Number of subjects: 0
Study 31524435 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate punishment (answering repetitive questions)
Number of subjects: 164
Study 31524435 — intervention group
Group type: COMPARATOR
Intervention: Future punishment (meeting with a police officer in several weeks)
Number of subjects: 164
Study 29267025 — intervention group
Group type: EXPERIMENTAL
Intervention: Phospholipid fatty acid (PLFA) profiles measured in plasma
Number of subjects: 20
Study 29267025 — intervention group
Group type: EXPERIMENTAL
Intervention: Phospholipid fatty acid (PLFA) profiles measured in prostate tissue
Number of subjects: 20
Study 29267025 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean tissue PLFA concentrations
Number of subjects: 20
Study 28994212 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant biochemotherapy (BCT)
Number of subjects: 402
Study 28994212 — intervention group
Group type: COMPARATOR
Intervention: High-dose interferon alfa-2B (HDI)
Number of subjects: 402
Study 28994212 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (BCT and HDI)
Number of subjects: 402
Study 25188488 — intervention group
Group type: EXPERIMENTAL
Intervention: Sponge model
Number of subjects: 2
Study 25188488 — intervention group
Group type: EXPERIMENTAL
Intervention: Beef tongue model
Number of subjects: 2
Study 25188488 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue model after sponge model
Number of subjects: 2
Study 25188488 — intervention group
Group type: EXPERIMENTAL
Intervention: Both models
Number of subjects: 2
Study 23695200 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term treatment with 40 mg of prednisone daily for 5 days
Number of subjects: 314
Study 23695200 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment with 40 mg of prednisone daily for 14 days
Number of subjects: 314
Study 20943046 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg twice weekly for 12 weeks
Number of subjects: 20
Study 20943046 — intervention group
Group type: EXPERIMENTAL
Intervention: Acitretin 0.4 mg/kg per day for 12 weeks
Number of subjects: 20
Study 20943046 — intervention group
Group type: COMPARATOR
Intervention: Control group (Atopic Dermatitis)
Number of subjects: 20
Study 18725146 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided experiential assignment with older adults (n = 52)
Number of subjects: 100
Study 18725146 — intervention group
Group type: COMPARATOR
Intervention: Guided experiential assignment with younger adults (n = 48)
Number of subjects: 100
Study 16608948 — intervention group
Group type: EXPERIMENTAL
Intervention: superDimension/Bronchus system (SDBS)
Number of subjects: 13
Study 14616416 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole 200 mg twice daily + Indinavir 800 mg three times daily (Study A)
Number of subjects: 32
Study 14616416 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole 200 mg twice daily + Indinavir 800 mg three times daily (Study B)
Number of subjects: 32
Study 14616416 — intervention group
Group type: COMPARATOR
Intervention: Voriconazole 200 mg twice daily + Placebo (Study A)
Number of subjects: 32
Study 14616416 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir 800 mg three times daily + Voriconazole 200 mg (Study B)
Number of subjects: 32
Study 14616416 — intervention group
Group type: COMPARATOR
Intervention: Indinavir 800 mg three times daily + Placebo (Study B)
Number of subjects: 32
Study 11025238 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ephedrine (10 mg)
Number of subjects: 40
Study 11025238 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 40
Study 8157385 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic training
Number of subjects: 21
Study 8157385 — intervention group
Group type: COMPARATOR
Intervention: Ergometric training
Number of subjects: 21
Study 3277079 — intervention group
Group type: COMPARATOR
Intervention: Low-dose beta-blockers
Number of subjects: 0
Study 3277079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29274617 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 5709
Study 29274617 — intervention group
Group type: COMPARATOR
Intervention: Exemestane
Number of subjects: 5709
Study 28835218 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized palliative rehabilitation intervention integrated in standard oncology care
Number of subjects: 300
Study 28835218 — intervention group
Group type: COMPARATOR
Intervention: Standard oncology care alone
Number of subjects: 300
Study 28179349 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose RSB analgesia
Number of subjects: 56
Study 28179349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 28179349 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated-dose RSB analgesia
Number of subjects: 56
Study 28179349 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion RSB analgesia
Number of subjects: 56
Study 28179349 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall satisfaction measured by NRS
Number of subjects: 56
Study 23720347 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (TZ) treatment for 4-7 months
Number of subjects: 4
Study 23720347 — intervention group
Group type: COMPARATOR
Intervention: Before treatment (baseline)
Number of subjects: 4